Business
Collision 2022 - Day One
Snowflake CEO Sridhar Ramaswamy (Eóin Noonan / Getty Images)
Weird Money

Snowflake’s business is selling its own stock to employees

Snowflake's stock-based compensation has been more than 40% of its revenues since going public, and investors are losing their patience.

Jack Raines

A favorite accounting trick for publicly-traded companies is to exclude stock-based compensation from EBITDA and cash flow to paint an optimistic picture of company performance. For example, if a company’s net income is negative, but its stock-based compensation is larger than its net loss, adding back stock-based compensation in your financial statements can give you positive operating cash flow. The (incredibly-oversimplified) rationale is, “We’re not actually spending money, we’re just issuing new shares to employees. Why waste time focusing on stock-based comp?” Neat trick, right?

A different, but related, trick that companies love is to announce share buybacks to distract investors from high levels of stock-based compensation. Basically, company management will announce that it’s buying back, like, $500 million of stock, which sounds really good! Except, if the company’s stock-based compensation is more than $500 million over that period, it’s still a net-negative for investors. Think about it like this: while, yes, stock-based compensation is not a “cash expense” for the company, it is a very real expense for shareholders, because their stake in the company gets diluted.

On Wednesday, Snowflake, a data warehouse provider that went public in 2020, reported its Q2 2025 (its 2024 fiscal year ended on January 31, 2024) earnings, and the results were a masterclass in redistributing wealth from shareholders to employees. Snowflake’s stock-based compensation for the quarter was ~$373 million, or 43% of its $869 million in revenue. This matches a trend from the last three years, where Snowflake’s full-year stock-based compensation was 55%, 43%, and 44% of revenues in 2022, 2023, and 2024, respectively.

For context, Snap, which has long been cited as one of the more egregious examples of high stock-based compensation, had stock-based compensation worth 20% of revenue last quarter, compared to 30% last year.

Snowflake announced a $2.5 billion share buyback plan that expires in March 2027, which sounds nice, except the company’s total stock-based compensation over the last three years was approximately $2.8 billion. If this quarter’s equity compensation of $373 million is held constant through March 2027, more than $4 billion in new equity will be issued, and equity comp has only increased since the company went public. Buybacks sound nice, but they don’t mean much for investors if they fail to offset new issuances.

Snowflake lost ~$318 million on the quarter for a -36% profit margin, but if you removed stock-based compensation, the company would have posted a ~$56 million profit. It’s no surprise that investors are growing tired after three years of Snowflake awarding more than 40% of revenue as equity compensation as it remains  an unprofitable company with slowing revenue growth. The stock fell as much as 13% today, and it’s down more than 50% from its IPO.

If Snowflake’s new CEO wants to fix his stock price, he should start by reconsidering insiders’ equity grants.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.